

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/829,042
		Filing Date	April 21, 2004
		First Named Inventor	Trevor Barrowcliffe
		Art Unit	1652
		Examiner Name	Hope A. Robinson
Attorney Docket Number	674583-2001		
Sheet	1	of	1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ABSTRACT: M. Shima, et al., The Current Situation And Vision Of Plasma Protein Formulation..., Biomedical Perspectives (1999) Vol. 8, No. 1, p. 99-107	✓
		ABSTRACT: A. Yoshioka, Recombinant Factor VIII, 8. Recombinant Factor VIII Formulation, Jap. J. Transfus. Med. (1992) Vol. 38, No. 6, p. 845-849	✓
		ABSTRACT: M. Arai, The Current Situation And Vision Of Plasma Protein...; Biomed. Perspect. (1999) Vol. 9, No. 1, p. 108-117	✓

Examiner Signature	/Hope Robinson/	Date Considered	03/07/2011
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.